{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rasagiline+mesylate&page=2",
    "query": {
      "intervention": "rasagiline mesylate",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rasagiline+mesylate&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rasagiline+mesylate&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T06:30:36.370Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00492336",
      "title": "Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "rasagiline (Pharmacodynamics)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 84,
      "start_date": "2007-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Catonsville",
          "state": "Maryland"
        },
        {
          "city": "Dundalk",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492336"
    },
    {
      "nct_id": "NCT00203164",
      "title": "Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "rasagiline mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2002-05",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2010-03-09",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 6,
      "location_summary": "Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203164"
    },
    {
      "nct_id": "NCT02359552",
      "title": "Rasagiline Rescue in Alzheimer's Disease Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2015-05",
      "completion_date": "2019-01-04",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 3,
      "location_summary": "Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Lakewood",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02359552"
    },
    {
      "nct_id": "NCT01879748",
      "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-06",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-20",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879748"
    },
    {
      "nct_id": "NCT02278588",
      "title": "Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 45,
      "start_date": "2014-11",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278588"
    },
    {
      "nct_id": "NCT01786603",
      "title": "Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard Barohn, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-11-21",
      "completion_date": "2016-07-27",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786603"
    },
    {
      "nct_id": "NCT01968460",
      "title": "Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharma Two B Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 149,
      "start_date": "2013-12",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968460"
    },
    {
      "nct_id": "NCT01168596",
      "title": "Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-12",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Gainesville, Florida • Cleveland, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168596"
    },
    {
      "nct_id": "NCT00936676",
      "title": "ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "rasagiline mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 684,
      "start_date": "2009-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2016-04-11",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936676"
    },
    {
      "nct_id": "NCT01049984",
      "title": "Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Neuroscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2009-12",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-10-01T06:30:36.370Z",
      "location_count": 58,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049984"
    }
  ]
}